https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Immunol. Res. 2006;36(1-3):265-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Immunol. Res. 2006;36(1-3):265-742006-01-01 00:00:002019-02-15 09:15:12Understanding and exploiting dendritic cells in human immunodeficiency virus infection using the nonhuman primate model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / J Gene Med 2006 Jan;8(1):3-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / J Gene Med 2006 Jan;8(1):3-172006-01-01 00:00:002019-02-15 09:15:18From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Adv. Immunol. 2006;90:243-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Adv. Immunol. 2006;90:243-952006-01-01 00:00:002019-02-15 09:19:49Immunity to melanoma antigens: from self-tolerance to immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Biol. Pharm. Bull. 2006 Jan;29(1):100-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Biol. Pharm. Bull. 2006 Jan;29(1):100-42006-01-01 00:00:002019-02-15 09:19:53Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-172006-01-01 00:00:002019-02-15 09:24:18Immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Cytotherapy 2006;8(3):277-89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Cytotherapy 2006;8(3):277-892006-01-01 00:00:002019-02-15 08:51:01Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-37
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-372006-01-01 00:00:002019-02-15 08:51:02Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8808-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8808-152005-12-15 00:00:002019-02-15 09:25:39Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8763-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8763-722005-12-15 00:00:002019-02-15 09:25:40Natural killer cells license dendritic cell cross-presentation of B lymphoma cell–associated antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-182005-12-06 00:00:002019-02-15 09:19:47Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells
